KaloBios Pharma (KBIO) Remains on Track in Progress to IND & NDA Submissions for Benznidazole
Tweet Send to a Friend
KaloBios Pharmaceuticals, Inc. (KBIO) today provided an update on the company’s progress advancing its lead program benznidazole for the treatment ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
